What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.
How this was made

The 30-second read
Why it matters
Near-term trading is likely driven by updated financial guidance (gross-to-net toward lower end, cash and expense ranges) and by event-risk items: Q4 Phase II top-line timing for VOQUEZNA in EoE and the outcome risk of BDR Pharmaceuticals’ lawsuit challenging FDA’s application of the GAIN Act to extend NCE exclusivity.
Market read
This is a company-specific earnings-call update with concrete guidance and a clear set of upcoming clinical and legal catalysts that can shift probability-weighted valuation.
What to watch
The margin miss is attributed to one-time manufacturing charges, so traders may discount it, but any recurrence risk is not fully quantified; also, the cash covenant discussion reduces financing overhang but does not remove future dilution risk if clinical timelines slip.
Background
The call covers commercial execution for Voquezna (vonoprazan), cash and expense guidance, upcoming Phase II/III planning for EoE and NERD, and FDA exclusivity litigation tied to the GAIN Act.
Ticker impact
Phathom guided full-year gross-to-net discount toward the lower end of 55% to 59%, and reiterated cash expense and cash runway under its financing agreement.
Likely modest support as investors price in lower gross-to-net discount and sufficient cash, offset by uncertainty around exclusivity litigation outcomes and timing of next clinical readouts.
The article provides specific updated financial expectations (gross-to-net toward lower end, cash and expense guidance) plus concrete upcoming catalysts (Q4 Phase II top-line, 2027 Phase III discussion) and a named FDA exclusivity lawsuit that can affect commercial durability.
Market effects
Biopharma investors may recalibrate read-through on GI acid-blocker competitive durability and the litigation risk premium around exclusivity extensions.
Limited, primarily US small/mid-cap biotech sentiment.
Low, as the catalysts and litigation are US FDA and US commercial execution focused.
Counterpoint
Even with lower gross-to-net expectations, the stock may trade more on exclusivity litigation and the probability-weighted path to Phase III, which can dominate near-term valuation.
Key entities
- companyPhathom Pharmaceuticals
NASDAQ-listed biopharma focused on gastrointestinal treatments, principal product Voquezna (vonoprazan).
- productVOQUEZNA (vonoprazan)
Phathom’s potassium-competitive acid blocker; subject of exclusivity litigation and upcoming EoE Phase II readouts.
- companyBDR Pharmaceuticals
Filed suit against the FDA on Oct. 21 challenging the application of the GAIN Act to extend NCE exclusivity for VOQUEZNA tablets.
- regulatorFDA
Previously concluded that 10 years of NCE exclusivity as extended by the GAIN Act applies to products containing vonoprazan.


